Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hyaluronic acid/triamcinolone - Anika Therapeutics

Next Previous
Drug Profile

Hyaluronic acid/triamcinolone - Anika Therapeutics

Alternative Names: Cingal; Sodium hyaluronate/triamcinolone hexacetonide; Triamcinolone/Hyaluronic acid - Anika Therapeutics; Trispan

Latest Information Update: 10 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anika Therapeutics
  • Class Adjuvants; Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Glycosaminoglycans; Pregnadienes; Small molecules; Urologics
  • Mechanism of Action Glucocorticoid receptor agonists; Hyaluronic acid replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Osteoarthritis

Most Recent Events

  • 08 Aug 2023 Anika attendes a Type-C meeting with the US FDA
  • 01 Nov 2022 Hyaluronic acid/triamcinolone - Anika Therapeutics is available for licensing in USA, Asia as of 01 Nov 2022. www.anika.com, 9372281
  • 01 Nov 2022 Anika Therapeutics plans to discuss the pathway for US regulatory approval for hyaluronic acid/triamcinolone with the US FDA in 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top